Metropolis Healthcare has announced strong financial results for Q3FY26, with revenue increasing by 26% YoY to ₹406 Crore and profit after tax (PAT) surging by 63%. This growth was driven by robust demand, deeper penetration in Tier II and III markets, and a favorable shift towards complex and specialized testing. The company also reported significant growth in its TruHealth and Specialty portfolios.
Financial Performance
Metropolis Healthcare reported a revenue of ₹406 Cr in Q3FY26, a 26% increase compared to the same period last year. EBITDA stood at ₹95 Cr, reflecting a growth of 32% YoY. The company’s profit after tax (PAT) surged by 63% YoY to ₹51 Cr.
Key Operational Highlights
Patient and Test Volumes grew by 14% and 13% YoY, respectively. B2C revenues increased by 19% YoY, while B2B revenues grew by approximately 35% YoY. TruHealth and Specialty portfolios experienced strong growth of approximately 37% and 34% YoY, respectively.
Revenue Growth Drivers
The company attributes its strong performance to steady demand trends, deeper penetration in Tier II and Tier III markets, and a favorable mix shift toward complex and specialized testing. Revenue per Test (RPT) and Revenue per Patient (RPP) increased by 11% and 10% YoY, respectively, supported by brand strength and higher adoption of advanced diagnostics.
Regional Performance & Expansion
North India’s revenue contribution stood at 17%. Tier III cities registered 16% revenue growth and contributed 24% to overall revenues. Recent acquisitions, including Scientific Pathology (Agra) and Dr. Ahuja’s Pathology & Imaging Center (Dehradun), and Dr. R. S. Patil’s Ambika Pathology Laboratory (Kolhapur), have been integrated as planned and continue to perform strongly.
Bonus Issue
The Board has approved a 3:1 bonus issue of equity shares.
Source: BSE
